Sichuan Huiyu's HY05350 Achieves First Patient Dosing in Phase I Trial for MSLN-Positive Tumors
CompanyDrug

Sichuan Huiyu’s HY05350 Achieves First Patient Dosing in Phase I Trial for MSLN-Positive Tumors

Zhaoke Ophthalmology's TONO-i Gains NMPA Approval for Glaucoma Management in China
CompanyDrug

Zhaoke Ophthalmology’s TONO-i Gains NMPA Approval for Glaucoma Management in China

Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau
CompanyDeals

Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau

Innovent Biologics' IBI3032 Receives IND Approval From FDA and NMPA for GLP-1RA Clinical Trials
CompanyDrug

Innovent Biologics’ IBI3032 Receives IND Approval From FDA and NMPA for GLP-1RA Clinical Trials

Dr. Noah Biotech Collaborates with Thermo Fisher to Accelerate Rare Disease Treatments
CompanyDeals

Dr. Noah Biotech Collaborates with Thermo Fisher to Accelerate Rare Disease Treatments

TenNor Therapeutics Submits Listing Application to Hong Kong Stock Exchange Main Board
CompanyDeals

TenNor Therapeutics Submits Listing Application to Hong Kong Stock Exchange Main Board

FDA Clears Elevidys Gene Therapy After Investigating 8-Year-Old Boy's Death
CompanyDrug

FDA Clears Elevidys Gene Therapy After Investigating 8-Year-Old Boy’s Death

Mabwell's CDH17-Targeted ADC 7MW4911 Receives Clinical Trial Approval in China and IND Clearance in the US
CompanyDrug

Mabwell’s CDH17-Targeted ADC 7MW4911 Receives Clinical Trial Approval in China and IND Clearance in the US

Cutia Therapeutics' CU-40102 Approved in Hong Kong for Androgenetic Alopecia Treatment
CompanyDrug

Cutia Therapeutics’ CU-40102 Approved in Hong Kong for Androgenetic Alopecia Treatment

UTC Therapeutics Gains FDA Clearance for CAR-T Therapy UCLM805 in MSLN-Positive Solid Tumors
CompanyDrug

UTC Therapeutics Gains FDA Clearance for CAR-T Therapy UCLM805 in MSLN-Positive Solid Tumors

FDA Mandates Safety Labeling Changes for Opioid Pain Medications and Targets 7-OH Products
CompanyDrug

FDA Mandates Safety Labeling Changes for Opioid Pain Medications and Targets 7-OH Products

Luye Pharma’s LY03021 Completes Enrollment of First Healthy Subject in Phase I Trial
CompanyDrug

Luye Pharma’s LY03021 Completes Enrollment of First Healthy Subject in Phase I Trial